Stock Analysis, Dividends, Split History

PSDV / pSivida Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)90.90
Enterprise Value ($M)69.44
Book Value ($M)11.69
Book Value / Share0.16
Price / Book7.78
NCAV ($M)-20.07
NCAV / Share-0.27
Price / NCAV-4.53
Share Statistics
Common Stock Shares Outstanding 74,512,048
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 74,512,048
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.83
Return on Assets (ROA)-2.85
Return on Equity (ROE)-3.99
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio1.84
Income Statement (mra) ($M)
License And Services Revenue0.00
Royalty Revenue0.00
Operating Income-26.27
Net Income-53.17
Earnings Per Share Basic And Diluted-1.15
Cash Flow Statement (mra) ($M)
Cash From Operations-21.91
Cash from Investing-16.89
Cash from Financing-16.89
Identifiers and Descriptors
Central Index Key (CIK)1314102
Related CUSIPS
74440J951 74440J901

Split History

Stock splits are used by pSivida Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
PSDV : pSivida Corporation Stock Analysis and Research Report

2017-10-20 - Asif

pSivida Corporation develop sustained-release drug delivery products that deliver drugs at a controlled and steady rate for months or years. pSivida hss developed three of the four sustained-release ophthalmic products currently approved by the U.S. FDA for treatment of back-of-the-eye diseases. Its product development programs are focused primarily on utilizing its core Durasert technology platform to deliver drugs to treat chronic diseases. Durasert three-year uveitis is its most advanced development-stage product, and is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis) for a period of three years. Durasert three-year uveitis met its primary efficacy endpoint of prevention of recurrence of uveitis through six months with a p value of < 0.001 in two ongoing pivotal Phase 3 clinical trials. pSivida anticipate filing an NDA with the FDA in late December 2017 or early January 2018. In July 2017, pSivida amended its co...

CUSIP: 74440J101